Selected recent publications
EAI-432, a mutant-selective allosteric EGFR inhibitor for L858R-mutant lung cancer. Scott, D; Gero, T; Jiang, J; Beyett, T; To, C; Heppner, D; Gokhalle, G; Gray, N; Jänne, P; Eck, M. Poster at Molecular Targets and Cancer Therapeutics (AACR – NCI – EORTC), Oct 2023.
Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC. Gero, T; Heppner, D; Beyett, T; To, C.; Azevedo, S; Jang, J; Bunnell, T; Feru, F; Li, Z.; Shin, B; Soroko, K; Gokhale, P; Gray, N; Jänne, P; Eck, M; Scott, D. Bioorg. Med. Chem. Lett. (2022) 68, 128718.
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer. To, C.; Beyett, T; Jang, J; Feng, W; Bahcall, M; Haikala, H. M; Shin, B; Heppner, D; Rana, J; Leeper, B; Soroko, K; Poitras, M; Gokhale, P; Kobayashi, Y; Wahid, K; Kurppa, K; Gero, T; Cameron, M; Ogino, A; Mushajiang, M; Xu, C; Zhang, Y; Scott, D; Eck, M; Gray, N; Jänne, P. Nat. Canc. (2022) 3, 402.
Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors. Beyett, T; To, C; Heppner, D; Rana, J; Schmoker, A; Jang, J; De Clercq, D; Gomez, G; Scott, D; Gray, N; Jänne, P; Eck, M. Nat. Comm. (2022), 13, 2530.
Discovery of a Pyrimidothiazolodiazepinone as a potent and selective Focal Adhesion Kinase (FAK) Inhibitor. Groendyke, B.; Nabet, B.; Mohardt, M.; Zhang, H.; Peng, K.; Koide, E.; Coffey, C.; Che, J.; Scott, D.; Bass, A.; Gray, N. ACS Med. Chem. Lett. (2021), 12, 30-38.
Discovery of a series of benzopyrimidodiazepinone TNK2 inhibitors via scaffold morphing. Li, Z.; Powell, C. E.; Groendyke, B. J.; Gero, T. W.; Feru, F.; Feutrill, J.; Chen, B.; Li, B.; Szabo, H.; Gray, N. S.; Scott, D. A. Bioorg. Med. Chem. Lett. (2020), 31, 127456.
Hatcher, J.M.; Yang, G.; Buhrlage, S.; Yang, G. Treon, S. Gray, N.S. Discovery of a selective, covalent IRAK1 inhibitor with antiproliferative activity in MYD88 mutated B-cell lymphoma. ACS Med. Chem. Lett. (2020), 11, 2238–2243.
Exploring targeted degradation strategy for oncogenic KRAS G12C. Zeng, M.; Xiong, Y.; Safaee, N.; Nowak, R. P.; Donovan, K. A.; Yuan, C. J.; Nabet, B.; Gero, T.G.; Feru, F.; Li, L.; Gondi, S.; Ombelets, L. J.; Quan, C.; Jänne, P. A.; Kostic, M.; Scott, D. A.; Westover, K. D.; Fischer, E. S; Gray, N. S. Cell Chem. Biol. (2020); 27, 19-31.
Development and Characterization of a Wee1 Kinase Degrader. Li Z.; Pinch, B. J.; Olson, C.; Donovan, K. A.; Nowak, R. P.; Mills, C.; Scott, D.; Doctor, Z. M.; Eleuteri, N. A.; Chung, M.; Sorger, P.; Fischer, E. S.; Gray, N. S. Cell Chem. Biol. (2020), 27, 57-65.
Benzopyrimidodiazepinone inhibitors of TNK2. Groendyke, B. J.; Powell, C. E.; Feru, F.; Gero, T. W.; Li, Z.; Szabo, H.; Pang, K.;Feutrill, J.; Chen, B.; Li, B.; Gray, N. S.; Scott, D. A. Bioorg. Med. Chem. Lett. (2019), 30, 126948.
Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-selective EGFR Inhibitors. De Clercq, D. J. H.; Heppner, D. E.; To, C.; Jang, J.; Park, E.; Yun, C.-H.; Mushajiang, M.; Shin, B. H.; Scott, D. A.; Jänne, P. A.; Eck, M. J.; Gray N. S. ACS Med. Chem. Lett. (2019), 10, 1549-1553.
Quinoline and thiazolopyridine allosteric inhibitors of MALT1. Scott, D. A.; Hatcher, J. M.; Liu, H.; Du, G.; Fontan, L.; Us, I.; Casalena, G.; Qiao, Q.; Wu, H.; Melnick, A.; Gray, N. S. Bioorg. Med. Chem. Lett. (2019), 29, 1694-1698.
Peptide-based covalent inhibitors of MALT1 paracaspase. Hatcher, J. M.; Du, G.; Fontan, L.; Us, I.; Qiao, Q.; Chennamadhavuni, S.; Shao, J.; Wu, H.; Melnick, A.; Gray, N. S.; Scott, D. A. Bioorg. Med. Chem. Lett. (2019), 29, 1336-1339.
Hatcher, J. M.; Wu, Guowei; Zeng, Chuyue; Zhu, Jie; Meng, Fan; Patel, Sherrina; Wang, Wenqiu; Ficarro, Scott B.; Leggett, Alan L.; Powell, Chelsea E.; Marto, Jarrod A.; Zhang, Kang; Ki Ngo, Jacky Chi; Fu, Xiang-Dong; Zhang, Tinghu; Gray, Nathanael S. SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform. Cell Chemical Biology (2018), 25, 460-470.
Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth. Fontan, L.; Qiao, Q.; Hatcher, J.; Casalena, G.; Us, I.; Durant, M.; Teater, M.; Durant, M.; Du, G.; Xia, M.; Bilchuk, N.; Chennamadhavuni, S.; Palladino, G.; Inghirami, G.; Philippar, U.; Wu, H.; Scott, D.A.; Gray, N.S.; Melnick, A. J. Clin. Invest. (2018), 128, 4397-4412.
Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC. Gero, T; Heppner, D; Beyett, T; To, C.; Azevedo, S; Jang, J; Bunnell, T; Feru, F; Li, Z.; Shin, B; Soroko, K; Gokhale, P; Gray, N; Jänne, P; Eck, M; Scott, D. Bioorg. Med. Chem. Lett. (2022) 68, 128718.
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer. To, C.; Beyett, T; Jang, J; Feng, W; Bahcall, M; Haikala, H. M; Shin, B; Heppner, D; Rana, J; Leeper, B; Soroko, K; Poitras, M; Gokhale, P; Kobayashi, Y; Wahid, K; Kurppa, K; Gero, T; Cameron, M; Ogino, A; Mushajiang, M; Xu, C; Zhang, Y; Scott, D; Eck, M; Gray, N; Jänne, P. Nat. Canc. (2022) 3, 402.
Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors. Beyett, T; To, C; Heppner, D; Rana, J; Schmoker, A; Jang, J; De Clercq, D; Gomez, G; Scott, D; Gray, N; Jänne, P; Eck, M. Nat. Comm. (2022), 13, 2530.
Discovery of a Pyrimidothiazolodiazepinone as a potent and selective Focal Adhesion Kinase (FAK) Inhibitor. Groendyke, B.; Nabet, B.; Mohardt, M.; Zhang, H.; Peng, K.; Koide, E.; Coffey, C.; Che, J.; Scott, D.; Bass, A.; Gray, N. ACS Med. Chem. Lett. (2021), 12, 30-38.
Discovery of a series of benzopyrimidodiazepinone TNK2 inhibitors via scaffold morphing. Li, Z.; Powell, C. E.; Groendyke, B. J.; Gero, T. W.; Feru, F.; Feutrill, J.; Chen, B.; Li, B.; Szabo, H.; Gray, N. S.; Scott, D. A. Bioorg. Med. Chem. Lett. (2020), 31, 127456.
Hatcher, J.M.; Yang, G.; Buhrlage, S.; Yang, G. Treon, S. Gray, N.S. Discovery of a selective, covalent IRAK1 inhibitor with antiproliferative activity in MYD88 mutated B-cell lymphoma. ACS Med. Chem. Lett. (2020), 11, 2238–2243.
Exploring targeted degradation strategy for oncogenic KRAS G12C. Zeng, M.; Xiong, Y.; Safaee, N.; Nowak, R. P.; Donovan, K. A.; Yuan, C. J.; Nabet, B.; Gero, T.G.; Feru, F.; Li, L.; Gondi, S.; Ombelets, L. J.; Quan, C.; Jänne, P. A.; Kostic, M.; Scott, D. A.; Westover, K. D.; Fischer, E. S; Gray, N. S. Cell Chem. Biol. (2020); 27, 19-31.
Development and Characterization of a Wee1 Kinase Degrader. Li Z.; Pinch, B. J.; Olson, C.; Donovan, K. A.; Nowak, R. P.; Mills, C.; Scott, D.; Doctor, Z. M.; Eleuteri, N. A.; Chung, M.; Sorger, P.; Fischer, E. S.; Gray, N. S. Cell Chem. Biol. (2020), 27, 57-65.
Benzopyrimidodiazepinone inhibitors of TNK2. Groendyke, B. J.; Powell, C. E.; Feru, F.; Gero, T. W.; Li, Z.; Szabo, H.; Pang, K.;Feutrill, J.; Chen, B.; Li, B.; Gray, N. S.; Scott, D. A. Bioorg. Med. Chem. Lett. (2019), 30, 126948.
Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-selective EGFR Inhibitors. De Clercq, D. J. H.; Heppner, D. E.; To, C.; Jang, J.; Park, E.; Yun, C.-H.; Mushajiang, M.; Shin, B. H.; Scott, D. A.; Jänne, P. A.; Eck, M. J.; Gray N. S. ACS Med. Chem. Lett. (2019), 10, 1549-1553.
Quinoline and thiazolopyridine allosteric inhibitors of MALT1. Scott, D. A.; Hatcher, J. M.; Liu, H.; Du, G.; Fontan, L.; Us, I.; Casalena, G.; Qiao, Q.; Wu, H.; Melnick, A.; Gray, N. S. Bioorg. Med. Chem. Lett. (2019), 29, 1694-1698.
Peptide-based covalent inhibitors of MALT1 paracaspase. Hatcher, J. M.; Du, G.; Fontan, L.; Us, I.; Qiao, Q.; Chennamadhavuni, S.; Shao, J.; Wu, H.; Melnick, A.; Gray, N. S.; Scott, D. A. Bioorg. Med. Chem. Lett. (2019), 29, 1336-1339.
Hatcher, J. M.; Wu, Guowei; Zeng, Chuyue; Zhu, Jie; Meng, Fan; Patel, Sherrina; Wang, Wenqiu; Ficarro, Scott B.; Leggett, Alan L.; Powell, Chelsea E.; Marto, Jarrod A.; Zhang, Kang; Ki Ngo, Jacky Chi; Fu, Xiang-Dong; Zhang, Tinghu; Gray, Nathanael S. SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform. Cell Chemical Biology (2018), 25, 460-470.
Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth. Fontan, L.; Qiao, Q.; Hatcher, J.; Casalena, G.; Us, I.; Durant, M.; Teater, M.; Durant, M.; Du, G.; Xia, M.; Bilchuk, N.; Chennamadhavuni, S.; Palladino, G.; Inghirami, G.; Philippar, U.; Wu, H.; Scott, D.A.; Gray, N.S.; Melnick, A. J. Clin. Invest. (2018), 128, 4397-4412.